R2810-ONC-1788/TROG 17.11 - CPOST - TROG Cancer Research

By w.paterson
21 June, 2021
0 Comments

A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

Primary Sponsor

Collaborating Groups

TROG Cancer Research

Accrual Target

412

Final Accrual

415

Closing Date of Accrual

20 August 2024

Trial Chairperson

Prof Sandro Porceddu - Princess Alexandra Hospital

Trial Contact

qa@trog.com.au

Prof Paul Keall, Image X Director and VITaL trial chief investigator

15 May, 2025

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

LATEST NEWS: 15 May 2025 A novel imaging modality

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

TROG 18.06 – FIG

TROG 20.03 – AVATAR

Related Post

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

Trial data-sharing made easier with HeSANDA initiative